MS and Demyelinating Disorders

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

The professor of neurology at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Anti–IL-6R receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.